Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice.
Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 x 10(8) CFU.
Gunn
Bronwyn M
BM
The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
Wanda
Soo-Young
SY
Burshell
Dana
D
Wang
Caihong
C
Curtiss
Roy
R
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology*; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D005260:Female; D005798:Genes, Bacterial; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D022562:Salmonella Vaccines / Q000276:immunology*; D012486:Salmonella typhimurium / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D000942:Antigens, Bacterial; D022562:Salmonella Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic